Seouleaguer Co Ltd

Seouleaguer Co Ltd exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 4.21, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.39 and negative free cash flow of -72.24 billion KRW, which suggests that the company is not generating sufficient cash from operations to cover its short-term obligations. The price-to-book ratio of 10.83 implies that the market is valuing the company's equity at a premium to its book value, despite the company's negative net income and operating income.

Profitability metrics for Seouleaguer Co Ltd are severely negative, with a return on equity of -24.46% and a return on assets of -3.86%, both of which are well below the industry norms for drug retailers. The company's operating margin is also negative, with an operating loss of -11.66 billion KRW, which is a significant drag on its financial performance. These figures indicate that the company is not only failing to generate returns for its shareholders but is also incurring substantial losses that could erode its equity base over time.

Geographically and segment-wise, the company's revenue is concentrated in a single business line, as disclosed in its financial statements, with no material diversification across regions or product categories. This lack of diversification increases the company's exposure to market-specific risks, such as regulatory changes or shifts in consumer demand, which could disproportionately impact its revenue streams. The company's financial snapshot does not provide detailed segment or geographic breakdowns, but the absence of such data suggests a lack of transparency or strategic diversification.

The company's growth trajectory is negative, with a net income of -8.74 billion KRW and an operating income of -11.66 billion KRW, indicating a decline in profitability. The company's revenue of 35.67 billion KRW is not sufficient to offset its operating and financial costs, which are significantly higher than its revenue. The outlook for the company's revenue and profitability is bleak, with no signs of improvement in the near term. The company's capital expenditures of -6.59 billion KRW suggest that it is not investing in growth initiatives, which could further hinder its ability to recover from its current financial position.

The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The risk assessment indicates that the company is facing significant financial stress, which could lead to liquidity constraints and potential insolvency if not addressed. The dilution risk is currently low, but the company's high debt levels and negative cash flows could necessitate future equity issuances, which would dilute existing shareholders. The company's financial performance and risk factors suggest that it is in a precarious position, with limited capacity to withstand further financial shocks.

Recent events and filings indicate that the company is experiencing financial distress, as evidenced by its negative earnings and cash flows. The company's last actual EPS was -257.00 KRW, which is a clear indicator of its inability to generate profits. The company's financial statements and risk assessment suggest that it is in a state of financial decline, with no immediate signs of recovery. The company's management may need to implement significant cost-cutting measures or seek external financing to stabilize its financial position.